Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Desoximetasone
Drug ID BADD_D00620
Description A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.
Indications and Usage For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Marketing Status approved
ATC Code D07AC03; D07XC02
DrugBank ID DB00547
KEGG ID D03697
MeSH ID D003899
PubChem ID 5311067
TTD Drug ID D0CZ1Q
NDC Product Code 45802-496; 51672-5204; 63629-8642; 68180-949; 70771-1166; 40032-024; 0168-0180; 70771-1437; 50090-5571; 51672-1270; 51672-1396; 63187-646; 71205-271; 64980-326; 51672-1261; 0472-0478; 72578-091; 0168-0151; 45802-495; 63629-8702; 68180-946; 68180-948; 0472-0479; 68180-950; 68462-531; 22552-0008; 51672-5202; 51672-5205; 51672-5281; 63629-8641; 64980-327; 72578-095; 51672-1352; 51672-5203; 53002-9280; 46439-8706; 51927-0187; 51672-1271; 51672-5263; 68180-944; 82298-112; 45802-807; 51672-1262
UNII 4E07GXB7AU
Synonyms Desoximetasone | Desoxymethasone | 17-Desoxymethasone | 17 Desoxymethasone | Deoxydexamethasone | Topicort | Stiedex | A-41304 | A 41304 | A41304 | Ibaril | Topisolon | Flubason | Topicorte | Desoxi
Chemical Information
Molecular Formula C22H29FO4
CAS Registry Number 140218-14-0
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1C(=O)CO)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Uveitis06.04.03.003; 10.02.01.023--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.018---
Multiple sclerosis relapse17.16.01.003---
Fibromyalgia15.05.02.002---
Skin maceration23.03.03.016---
Joint range of motion decreased15.01.02.006--
Poor venous access24.03.02.017---
Seasonal allergy06.04.01.013; 10.01.04.001; 22.04.04.008---
Application site dryness08.02.01.011; 12.07.01.011; 23.03.03.024---
Peripheral swelling02.05.04.015; 08.01.03.053---
Emotional distress19.04.02.008---
General physical health deterioration08.01.03.018---
Balance disorder08.01.03.081; 17.02.02.007---
Dysstasia08.01.03.089; 15.03.05.011; 17.02.02.012---
Ear discomfort04.03.01.005---
Ocular discomfort06.08.03.008---
Musculoskeletal stiffness15.03.05.027---
Musculoskeletal discomfort15.03.04.001---
Secretion discharge08.01.03.019---
Infusion site pain08.02.05.014; 12.07.05.002---
Haemorrhage24.07.01.002---
Hot flush08.01.03.027; 21.02.02.001; 24.03.01.005--
Cardiac disorder02.11.01.003---
Inflammation08.01.05.007; 10.02.01.089---
Malnutrition14.03.02.004---
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages